Brokers Set Expectations for TVTX FY2025 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Travere Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings per share of ($1.13) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.92) per share.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm had revenue of $62.90 million during the quarter, compared to the consensus estimate of $60.87 million. During the same quarter in the previous year, the firm posted ($1.17) EPS. The business’s revenue for the quarter was up 69.6% compared to the same quarter last year.

Several other brokerages have also recently weighed in on TVTX. Leerink Partners reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of Travere Therapeutics in a report on Tuesday, October 8th. Barclays upped their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Scotiabank raised their target price on shares of Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Citigroup dropped their target price on shares of Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, September 27th. Finally, Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Travere Therapeutics Trading Up 6.9 %

Shares of TVTX stock opened at $20.81 on Wednesday. The stock has a market cap of $1.62 billion, a P/E ratio of -4.57 and a beta of 0.70. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $20.89. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The stock has a 50 day simple moving average of $18.28 and a 200 day simple moving average of $14.79.

Insider Activity at Travere Therapeutics

In related news, insider Peter Heerma sold 1,584 shares of the firm’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $18.94, for a total value of $30,000.96. Following the completion of the transaction, the insider now owns 106,374 shares in the company, valued at $2,014,723.56. This trade represents a 1.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roy D. Baynes sold 16,000 shares of the business’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $20.00, for a total transaction of $320,000.00. Following the sale, the director now directly owns 31,000 shares in the company, valued at $620,000. The trade was a 34.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,143 shares of company stock valued at $1,167,512 in the last 90 days. 3.75% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently modified their holdings of TVTX. R Squared Ltd bought a new position in Travere Therapeutics during the 4th quarter worth $53,000. CWM LLC increased its stake in shares of Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after buying an additional 3,065 shares during the period. DRW Securities LLC bought a new position in shares of Travere Therapeutics during the second quarter worth about $95,000. Quarry LP acquired a new position in shares of Travere Therapeutics in the third quarter worth approximately $105,000. Finally, Forefront Analytics LLC boosted its holdings in Travere Therapeutics by 10.2% in the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after acquiring an additional 1,237 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.